Quality of Life in Patients With Bladder Cancer

Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00553215

Enrollment

2700

Registered

2007-11-05

Start date

2005-12-31

Completion date

Unknown

Last updated

2014-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

transitional cell carcinoma of the bladder, stage 0 bladder cancer, stage I bladder cancer, stage II bladder cancer

Brief summary

RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future. PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.

Detailed description

OBJECTIVES: * To study the effects of recurrence and progression on health-related quality of life (HRQL). * To study the effects of repeat cystoscopy on HRQL. * To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance. OUTLINE: This is a multicenter study. Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30. Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study. Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Interventions

PROCEDUREquality-of-life assessment

PROCEDUREquestionnaire administration

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: Inclusion criteria: * Enrolled on parent protocol CRUK-BCPP-2005-01 * Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria: * Non-muscle-invasive tumor * Muscle-invasive tumor * Solitary G1 pTa tumor

Exclusion criteria

* Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis PATIENT CHARACTERISTICS: Inclusion criteria: * Fit for cystoscopy and surgical biopsy/resection

Design outcomes

Primary

Measure	Time frame
Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026